- Report
- February 2024
- 70 Pages
Mexico
From €4128EUR$4,750USD£3,593GBP
- Report
- February 2024
- 70 Pages
Spain
From €4128EUR$4,750USD£3,593GBP
- Report
- February 2024
- 70 Pages
Vietnam
From €4128EUR$4,750USD£3,593GBP
- Report
- February 2024
- 70 Pages
Iran
From €4128EUR$4,750USD£3,593GBP
- Report
- February 2024
- 70 Pages
Brazil
From €4128EUR$4,750USD£3,593GBP
- Report
- February 2024
- 70 Pages
Russia
From €4128EUR$4,750USD£3,593GBP
- Report
- February 2024
- 70 Pages
Australia
From €4128EUR$4,750USD£3,593GBP
- Report
- February 2024
- 70 Pages
China
From €4128EUR$4,750USD£3,593GBP
- Report
- February 2024
- 70 Pages
Japan
From €4128EUR$4,750USD£3,593GBP
- Report
- February 2024
- 70 Pages
Japan
From €4128EUR$4,750USD£3,593GBP
- Report
- August 2023
- 70 Pages
Middle East, Africa
From €4128EUR$4,750USD£3,593GBP
- Report
- August 2023
- 70 Pages
Spain
From €4128EUR$4,750USD£3,593GBP
- Report
- August 2023
- 70 Pages
South Korea
From €4128EUR$4,750USD£3,593GBP
- Report
- October 2022
- 70 Pages
Africa
From €4128EUR$4,750USD£3,593GBP
- Report
- September 2025
- 101 Pages
Global
From €3500EUR$4,314USD£3,153GBP

Toujeo is a long-acting insulin used to treat adults with type 1 and type 2 diabetes. It is a part of the Endocrine and Metabolic Disorders Drugs market, which includes medications used to treat a variety of conditions, such as diabetes, thyroid disorders, and obesity. Toujeo is a once-daily, long-acting insulin that helps to control blood sugar levels. It is designed to provide a steady, consistent level of insulin throughout the day, helping to reduce the risk of hypoglycemia.
The Endocrine and Metabolic Disorders Drugs market is a rapidly growing sector, with a wide range of products available to treat a variety of conditions. Companies in this market include Sanofi, Novo Nordisk, Eli Lilly, Merck, and AstraZeneca. Show Less Read more